Multifunctional Liposomes Co-Modified with Ginsenoside Compound K and Hyaluronic Acid for Tumor-Targeted Therapy
Liposomes show promise for anti-cancer drug delivery and tumor-targeted therapy. However, complex tumor microenvironments and the performance limitations of traditional liposomes restrict clinical translation. Hyaluronic acid (HA)-modified nanoliposomes effectively target CD44-overexpressing tumor c...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-02-01
|
| Series: | Polymers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4360/16/3/405 |
| _version_ | 1797318302064705536 |
|---|---|
| author | Xiaoyan You Hui Liu Yue Chen Guoping Zhao |
| author_facet | Xiaoyan You Hui Liu Yue Chen Guoping Zhao |
| author_sort | Xiaoyan You |
| collection | DOAJ |
| description | Liposomes show promise for anti-cancer drug delivery and tumor-targeted therapy. However, complex tumor microenvironments and the performance limitations of traditional liposomes restrict clinical translation. Hyaluronic acid (HA)-modified nanoliposomes effectively target CD44-overexpressing tumor cells. Combination therapy enhances treatment efficacy and delays drug resistance. Here, we developed paclitaxel (PTX) liposomes co-modified with ginsenoside compound K (CK) and HA using film dispersion. Compared to cholesterol (Ch), CK substantially improved encapsulation efficiency and stability. In vitro release studies revealed pH-responsive behavior, with slower release at pH 7.4 versus faster release at pH 5. In vitro cytotoxicity assays demonstrated that replacing Ch with CK in modified liposomes considerably decreased HCT-116 cell viability. Furthermore, flow cytometry and fluorescence microscopy showed a higher cellular uptake of PTX-CK-Lip-HA in CD44-high cells, reflected in the lower half maximal inhibitory concentrations. Overall, CK/HA-modified liposomes represent an innovative, targeted delivery system for enhanced tumor therapy via pH-triggered drug release and CD44 binding. |
| first_indexed | 2024-03-08T03:50:28Z |
| format | Article |
| id | doaj.art-22d1123be67f4b9f8990bf999b43b40e |
| institution | Directory Open Access Journal |
| issn | 2073-4360 |
| language | English |
| last_indexed | 2024-03-08T03:50:28Z |
| publishDate | 2024-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Polymers |
| spelling | doaj.art-22d1123be67f4b9f8990bf999b43b40e2024-02-09T15:20:57ZengMDPI AGPolymers2073-43602024-02-0116340510.3390/polym16030405Multifunctional Liposomes Co-Modified with Ginsenoside Compound K and Hyaluronic Acid for Tumor-Targeted TherapyXiaoyan You0Hui Liu1Yue Chen2Guoping Zhao3College of Food and Bioengineering, Henan University of Science and Technology, Luoyang 471023, ChinaCollege of Food and Bioengineering, Henan University of Science and Technology, Luoyang 471023, ChinaTianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, Tianjin 300308, ChinaTianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, Tianjin 300308, ChinaLiposomes show promise for anti-cancer drug delivery and tumor-targeted therapy. However, complex tumor microenvironments and the performance limitations of traditional liposomes restrict clinical translation. Hyaluronic acid (HA)-modified nanoliposomes effectively target CD44-overexpressing tumor cells. Combination therapy enhances treatment efficacy and delays drug resistance. Here, we developed paclitaxel (PTX) liposomes co-modified with ginsenoside compound K (CK) and HA using film dispersion. Compared to cholesterol (Ch), CK substantially improved encapsulation efficiency and stability. In vitro release studies revealed pH-responsive behavior, with slower release at pH 7.4 versus faster release at pH 5. In vitro cytotoxicity assays demonstrated that replacing Ch with CK in modified liposomes considerably decreased HCT-116 cell viability. Furthermore, flow cytometry and fluorescence microscopy showed a higher cellular uptake of PTX-CK-Lip-HA in CD44-high cells, reflected in the lower half maximal inhibitory concentrations. Overall, CK/HA-modified liposomes represent an innovative, targeted delivery system for enhanced tumor therapy via pH-triggered drug release and CD44 binding.https://www.mdpi.com/2073-4360/16/3/405liposomescompound Ktumor-targeted therapyPTXhyaluronic acid |
| spellingShingle | Xiaoyan You Hui Liu Yue Chen Guoping Zhao Multifunctional Liposomes Co-Modified with Ginsenoside Compound K and Hyaluronic Acid for Tumor-Targeted Therapy Polymers liposomes compound K tumor-targeted therapy PTX hyaluronic acid |
| title | Multifunctional Liposomes Co-Modified with Ginsenoside Compound K and Hyaluronic Acid for Tumor-Targeted Therapy |
| title_full | Multifunctional Liposomes Co-Modified with Ginsenoside Compound K and Hyaluronic Acid for Tumor-Targeted Therapy |
| title_fullStr | Multifunctional Liposomes Co-Modified with Ginsenoside Compound K and Hyaluronic Acid for Tumor-Targeted Therapy |
| title_full_unstemmed | Multifunctional Liposomes Co-Modified with Ginsenoside Compound K and Hyaluronic Acid for Tumor-Targeted Therapy |
| title_short | Multifunctional Liposomes Co-Modified with Ginsenoside Compound K and Hyaluronic Acid for Tumor-Targeted Therapy |
| title_sort | multifunctional liposomes co modified with ginsenoside compound k and hyaluronic acid for tumor targeted therapy |
| topic | liposomes compound K tumor-targeted therapy PTX hyaluronic acid |
| url | https://www.mdpi.com/2073-4360/16/3/405 |
| work_keys_str_mv | AT xiaoyanyou multifunctionalliposomescomodifiedwithginsenosidecompoundkandhyaluronicacidfortumortargetedtherapy AT huiliu multifunctionalliposomescomodifiedwithginsenosidecompoundkandhyaluronicacidfortumortargetedtherapy AT yuechen multifunctionalliposomescomodifiedwithginsenosidecompoundkandhyaluronicacidfortumortargetedtherapy AT guopingzhao multifunctionalliposomescomodifiedwithginsenosidecompoundkandhyaluronicacidfortumortargetedtherapy |